Cellular Biomedicine Group Inc (CBMG.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cellular Biomedicine Group announces acquisition of Immune Cell Therapy Technology and U.S. Patent


Monday, 4 Aug 2014 09:16am EDT 

Cellular Biomedicine Group Inc:Announced reaching an agreement to acquire Agreen Biotech Co. Ltd. China (AG) and its founder's U.S. patent.For a total cash and equity consideration of $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.Acquisition will include the Intellectual Properties (IP), assets and talents of this cancer-therapy-focused developmental stage company.Expects to close the transaction and add 33 employees in the third quarter of 2014.